CMPS vs. BHC, BEAM, ARQT, BHVN, SDGR, EWTX, JANX, ETNB, ADPT, and DYN
Should you be buying COMPASS Pathways stock or one of its competitors? The main competitors of COMPASS Pathways include Bausch Health Companies (BHC), Beam Therapeutics (BEAM), Arcutis Biotherapeutics (ARQT), Biohaven (BHVN), Schrödinger (SDGR), Edgewise Therapeutics (EWTX), Janux Therapeutics (JANX), 89bio (ETNB), Adaptive Biotechnologies (ADPT), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical products" industry.
COMPASS Pathways vs.
COMPASS Pathways (NASDAQ:CMPS) and Bausch Health Companies (NYSE:BHC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, community ranking, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.
COMPASS Pathways has a net margin of 0.00% compared to Bausch Health Companies' net margin of -0.48%. COMPASS Pathways' return on equity of -63.85% beat Bausch Health Companies' return on equity.
Bausch Health Companies received 291 more outperform votes than COMPASS Pathways when rated by MarketBeat users. However, 82.14% of users gave COMPASS Pathways an outperform vote while only 60.91% of users gave Bausch Health Companies an outperform vote.
Bausch Health Companies has higher revenue and earnings than COMPASS Pathways. Bausch Health Companies is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks.
COMPASS Pathways has a beta of 2.25, indicating that its stock price is 125% more volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500.
In the previous week, Bausch Health Companies had 3 more articles in the media than COMPASS Pathways. MarketBeat recorded 4 mentions for Bausch Health Companies and 1 mentions for COMPASS Pathways. Bausch Health Companies' average media sentiment score of 1.56 beat COMPASS Pathways' score of 0.00 indicating that Bausch Health Companies is being referred to more favorably in the news media.
COMPASS Pathways presently has a consensus target price of $18.83, suggesting a potential upside of 295.66%. Bausch Health Companies has a consensus target price of $7.42, suggesting a potential upside of 45.85%. Given COMPASS Pathways' stronger consensus rating and higher probable upside, equities research analysts plainly believe COMPASS Pathways is more favorable than Bausch Health Companies.
46.2% of COMPASS Pathways shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Companies shares are held by institutional investors. 3.9% of COMPASS Pathways shares are held by company insiders. Comparatively, 8.1% of Bausch Health Companies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Bausch Health Companies beats COMPASS Pathways on 9 of the 17 factors compared between the two stocks.
Get COMPASS Pathways News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMPS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
COMPASS Pathways Competitors List
Related Companies and Tools
This page (NASDAQ:CMPS) was last updated on 6/11/2025 by MarketBeat.com Staff
